New scan criteria could sharpen cancer response readings

NCT ID NCT06448208

Ongoing Knowledge-focused Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 24, 2026 · Updated 3 times

Summary

This study aims to create better guidelines for reading PET scans in people with neuroendocrine tumors. Researchers will compare new criteria against the current standard to see which better predicts if a tumor shrinks, grows, or stays the same. The study involves 11 participants who are already scheduled for standard treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could give doctors a more accurate way to read PET scans for neuroendocrine tumors, helping them better decide if a treatment is working.
What could go wrong: This is a very small study (11 people) that only tests a new way to look at scans, not a new treatment. The new criteria may not prove better than the current standard.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neuroendocrine neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROENDOCRINE TUMORS

Contacts and locations

Locations

Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.